Clinical trial · Observational
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases
Targeting SMYD3-Driven Metabolic Rewiring and Oxidative Stress Adaptation in Colorectal Liver Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study focuses on patients with colorectal cancer undergoing surgery for the primary tumor and/or liver metastases. Tumor samples collected during surgery will be used to generate patient-derived models (primary cultures, spheroids, and organoids) to study colorectal cancer stem cells. The main objective is to investigate the role of the lysine methyltransferase SMYD3 in metabolic reprogramming and adaptation to oxidative stress that enable colorectal cancer cells to survive and grow in the liver. Previous work has shown that SMYD3 is overexpressed in colorectal cancer, promotes drug resistance, and regulates key oncogenic pathways, including c-MYC and the AMPK/mTOR axis. By identifying SMYD3-dependent pathways and pharmacologic vulnerabilities in cancer stem cells within liver metastases, this study aims to support the development of new therapeutic strategies that combine SMYD3 inhibitors with approved or experimental agents targeting tumor metabolism and oxidative stress responses
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CRC (Colorectal Cancer) | Colorectal Carcinoma | ALIAS | 0.85 |
| Liver Metastases From Colorectal Primary Cancer | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Patients with CRC (colorectal cancer)
- description
- Patients undergoing surgery for primary colorectal carcinoma, without liver metastases
- label
- Patients with colorectal cancer (CRC) and liver metastase
- description
- Patients undergoing surgery for primary colorectal carcinoma who simultaneously present liver metastases from colorectal carcinoma. In this case, tissue samples will be taken from both the colorectal carcinoma and the liver metastases
- label
- Patients with liver metastase
- description
- Patients undergoing surgery for the resection of liver metastases from previously operated colorectal cancer
Primary outcomes (1)
- measure
- Molecular and Cellular mechanisms
- timeFrame
- At the time of the surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Common criteria * Age ≥ 18 years. * Availability of residual tumor tissue from the surgical procedure that is not required for diagnostic purposes. * Signed written informed consent for the use of biological samples for research purposes. Cohort/Arm 1 (Colon-rectal tumor resection) \- Patients undergoing surgical resection of colorectal cancer. Cohort/Arm 2 (Primary tumor and liver metastases resection) - Patients undergoing surgical resection of the primary colorectal tumor and liver metastases from colorectal carcinoma. Cohort/Arm 3 (Liver metastases resection only) \- Patients undergoing surgical resection of liver metastases from colorectal carcinoma previously resected at the primary site. Exclusion Criteria: * Age \< 18 years. * Undergoing surgical intervention for a malignancy other than those specified in the inclusion criteria. * Lack of signed informed consent
References
Publications (0)
Data not yet available